[Liver cirrhosis and liver cancer associated with viral hepatitis B and C in republic of Tatarstan]. / Tsirroz i rak pecheni, assotsiirovannye s virusnymi gepatitami B i C, v respublike Tatarstan.

Clinical and epidemiological data on 93 patients with liver cirrhosis, treated in the Gastroenterological Department of the Republican Clinical Hospital of the of the Republic of Tatarstan MoH in 1998-2000 were analyzed. The retrospective analysis of 856 cases of the liver cancer, diagnosed in the Republic of Tatarstan in 1996-2000, was made. In 20.4% of patients with liver cirrhosis and 16.2% of patients with liver cancer, registered in the Republic of Tatarstan, the serological markers of hepatitis B (HB) and hepatitis C (HC) were detected. The domination of HC markers was observed in the liver cirrhosis and that of HB markers in the cancer of the liver. The liver cirrhosis with HC markers was more often registered in the age group of 45-60 years and with HB markers at the age over 60 years, while the cancer of the liver was more often registered in persons aged 75 years and older. The necessity of introducing the official registration of the liver cirrhosis and cancer associated with chronic infection caused by hepatoviruses B and C is confirmed.

[Use of amixin in the therapy and prevention of some viral infections]. / Opyt primeneniia amiksina pri lechenii i profilaktike nekotorykh virusnykh infektsionnykh zabolevanii.

The trial of oral interferon inductor amixin for effectiveness in chronic viral hepatitis (CVH) and hemorrhagic fever with renal syndrome (HFRS) has shown that amixin in CVH improved general condition of the patients, removed yellowness of the skin and sclera, normalized activity of aminotransferases and blood bilirubin level. Virus replication was stopped in 25 and 1.6% in CVHB and CVGC, respectively. Amixin in HFRS was effective if received early. Preventive amixin therapy in population groups with high HFRS risk prevents development of HFRS and acute respiratory viral infection.